Cholesterol, HDL - Drug effects
Research News and Information

Sunday, November 22, 2009

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.

Nov 2009 OBJECTIVES: Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function. BACKGROUND: NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density ... Read more...

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

24 Oct 2009 BACKGROUND: The role of high-density lipoprotein cholesterol (HDL-C) as a therapeutic target to prevent cardiovascular (CV) events remains unclear. We examined data from the Framingham Offspring Study from 1975 through 2003 to determine whether ... Read more...

ApoB versus non-HDL-C: what to do when they disagree.

30 Aug 2009 The high correlation between apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) is the chief argument employed against introducing apoB into clinical practice. However, high correlation does mean that non-HDL-C and apoB ... Read more...

Latest indexed articles for 'Cholesterol, HDL - Drug effects'

These are the very latest articles for this heading:

• Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging. Nov 2009
• Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. Nov 2009
• Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. 24 Oct 2009
• ApoB versus non-HDL-C: what to do when they disagree. 30 Aug 2009
• Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. 30 Aug 2009
• Advances in the medical treatment of diabetic retinopathy. 30 Jul 2009
• Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. 29 Jun 2009
• [HDL-cholesterol: from risk factor to therapeutic target] 14 Jun 2009
• Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Jun 2009
• Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. 30 May 2009
• Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. 30 May 2009
• Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. 10 May 2009
• Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. 29 Apr 2009
• Iatrogenic severe depression of high-density lipoprotein cholesterol. 27 Apr 2009
• Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities. 30 Mar 2009
• Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. 3 Mar 2009
• Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. 27 Feb 2009
• Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy. 27 Feb 2009
• Modulatory effects of rutin on biochemical and hematological parameters in hypercholesterolemic Golden Syrian hamsters. 27 Feb 2009
• Effect of moderate alcoholic beverage consumption on insulin sensitivity in insulin-resistant, nondiabetic individuals. 27 Feb 2009

See a longer list of these articles.

Technical information about 'Cholesterol, HDL'

Definition: Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.

Registry Number: 0

Descriptor UI: D008076

Alternative terms: Cholesterol, HDL; High Density Lipoprotein Cholesterol; alpha-Lipoprotein Cholesterol; Cholesterol, alpha-Lipoprotein; alpha Lipoprotein Cholesterol; HDL Cholesterol; Cholesterol, HDL2; HDL(2) Cholesterol; HDL2 Cholesterol; Cholesterol, HDL3; HDL(3) Cholesterol; HDL3 Cholesterol;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D10.532.432.400; D10.570.938.208.270; D12.776.521.479.470;

History Note: 2007 (1985)